Education
About Us
Working with TipRanks
Follow Us
Elicio Therapeutics (ELTX)
NASDAQ:ELTX
Total Valuation
Elicio Therapeutics has a market cap or net worth of $125.26M. The enterprise value is $112.70M.
Market Cap$125.26M
Enterprise Value$112.70M
Share Statistics
Elicio Therapeutics has 15,996,976 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,996,976
Owned by Insiders35.05%
Owned by Institutions5.58%
Financial Efficiency
Elicio Therapeutics’s return on equity (ROE) is 4.59 and return on invested capital (ROIC) is -243.73%.
Return on Equity (ROE)4.59
Return on Assets (ROA)-1.84
Return on Invested Capital (ROIC)-243.73%
Return on Capital Employed (ROCE)-2.70
Revenue Per Employee0.00
Profits Per Employee-1.62M
Employee Count32
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Elicio Therapeutics is -1.20. Elicio Therapeutics’s PEG ratio is -0.31.
PE Ratio-1.20
PS Ratio0.00
PB Ratio11.39
Price to Fair Value-5.50
Price to FCF-3.27
Price to Operating Cash Flow-2.89
PEG Ratio-0.31
Income Statement
In the last 12 months, Elicio Therapeutics had revenue of 0.00 and earned -51.90M in profits. Earnings per share was -4.25.
Revenue0.00
Gross Profit0.00
Operating Income-44.99M
Pretax Income-51.90M
Net Income-51.90M
EBITDA-50.27M
Earnings Per Share (EPS)-4.25
Cash Flow
In the last 12 months, operating cash flow was -35.06M and capital expenditures -129.00K, giving a free cash flow of -38.30M billion.
Operating Cash Flow-35.06M
Free Cash Flow-38.30M
Free Cash Flow per Share-2.39
Dividends & Yields
Elicio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.41
52-Week Price Change-1.60%
50-Day Moving Average5.78
200-Day Moving Average5.91
Relative Strength Index (RSI)66.03
Average Volume (3m)36.86K
Important Dates
Elicio Therapeutics upcoming earnings date is Aug 8, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date―
Financial Position
Elicio Therapeutics as a current ratio of 1.80, with Debt / Equity ratio of 65.04%
Current Ratio1.80
Quick Ratio1.80
Debt to Market Cap0.34
Net Debt to EBITDA-0.17
Interest Coverage Ratio-98.87
Taxes
In the past 12 months, Elicio Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Elicio Therapeutics EV to EBITDA ratio is -1.41, with an EV/FCF ratio of -1.90.
EV to Sales0.00
EV to EBITDA-1.41
EV to Free Cash Flow-1.90
EV to Operating Cash Flow-1.91
Balance Sheet
Elicio Therapeutics has $18.35M in cash and marketable securities with $5.79M in debt, giving a net cash position of -$12.56M billion.
Cash & Marketable Securities$18.35M
Total Debt$5.79M
Net Cash-$12.56M
Net Cash Per Share-$0.79
Tangible Book Value Per Share-$0.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Elicio Therapeutics is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside38.02% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast27.65%